Arteriosclerosis and Thrombosis, Vol 11, 663-670, Copyright © 1991 by American Heart Association

ARTICLES

Homocysteine thiolactone disposal by human arterial endothelial cells and serum in vitro

NP Dudman, C Hicks, JF Lynch, DE Wilcken and J Wang
Department of Medicine, University of New South Wales, Prince Henry Hospital, Little Bay, Sydney, Australia.

Previous work with cultured mammalian cells and perfused laboratory animals suggested to us that hydrolysis of homocysteine thiolactone was catalyzed in these systems. We confirmed this finding by measuring the sulfhydryl-releasing activity of cultured endothelial cells from human umbilical arteries in homocysteine thiolactone solution, pH 7.4, 37 degrees C. The reaction was vigorous and stereospecific and showed saturation kinetics (Km values for L- and D,L-homocysteine thiolactone were 3.9 and 8.2 mmol/l, respectively, and Vmax values were 10.75 and 10.1 mumol/min/10(9) cells, respectively). L-Homocysteine thiolactone was quantitatively converted to homocysteine, as measured by amino acid analysis. Human serum also accelerated the elimination of homocysteine thiolactone, although in this process, the majority of the newly formed sulfhydryl-containing product was precipitable by sulfosalicylic acid, indicating likely homocysteinylation of serum proteins. However, approximately 38% of the sulfhydryl-containing product was not precipitated, and because thiolactone elimination stereospecifically favored the L-enantiomer, a possible subsidiary role for serum- catalyzed hydrolysis of the thiolactone was suggested. No homocysteine thiolactone could be found in serum samples from six patients with acute myocardial infarction, three patients with cystathionine beta- synthase deficiency, and six normal subjects. Thus, humans have active vascular systems for elimination of homocysteine thiolactone, a process that could be responsible for an absence of the compound in serum.

This article has been cited by other articles:

				N. F. Ford Clopidogrel Resistance: Pharmacokinetic or Pharmacogenetic? J. Clin. Pharmacol., May 1, 2009; 49(5): 506 - 512. [Abstract] [Full Text] [PDF]

				M R Graham, F M Grace, W Boobier, D Hullin, A Kicman, D Cowan, B Davies, and J S Baker Homocysteine induced cardiovascular events: a consequence of long term anabolic-androgenic steroid (AAS) abuse Br. J. Sports Med., July 1, 2006; 40(7): 644 - 648. [Abstract] [Full Text] [PDF]

				G. Chwatko and H. Jakubowski Urinary Excretion of Homocysteine-Thiolactone in Humans Clin. Chem., February 1, 2005; 51(2): 408 - 415. [Abstract] [Full Text] [PDF]

				V. Cavalca, G. Cighetti, F. Bamonti, A. Loaldi, L. Bortone, C. Novembrino, M. De Franceschi, R. Belardinelli, and M. D. Guazzi Oxidative Stress and Homocysteine in Coronary Artery Disease Clin. Chem., May 1, 2001; 47(5): 887 - 892. [Abstract] [Full Text] [PDF]

				S. E. Sanchez, C. Zhang, M. Rene Malinow, S. Ware-Jauregui, G. Larrabure, and M. A. Williams Plasma Folate, Vitamin B12, and Homocyst(e)ine Concentrations in Preeclamptic and Normotensive Peruvian Women Am. J. Epidemiol., March 1, 2001; 153(5): 474 - 480. [Abstract] [Full Text] [PDF]

				H. Jakubowski, L. Zhang, A. Bardeguez, and A. Aviv Homocysteine Thiolactone and Protein Homocysteinylation in Human Endothelial Cells : Implications for Atherosclerosis Circ. Res., July 7, 2000; 87(1): 45 - 51. [Abstract] [Full Text] [PDF]

				H. Jakubowski Calcium-dependent Human Serum Homocysteine Thiolactone Hydrolase. A PROTECTIVE MECHANISM AGAINST PROTEIN N-HOMOCYSTEINYLATION J. Biol. Chem., February 11, 2000; 275(6): 3957 - 3962. [Abstract] [Full Text] [PDF]

				C. L. Krumdieck and C. W. Prince Mechanisms of Homocysteine Toxicity on Connective Tissues: Implications for the Morbidity of Aging J. Nutr., February 1, 2000; 130(2): 365 - 365. [Abstract] [Full Text]

				H. Jakubowski Homocysteine Thiolactone: Metabolic Origin and Protein Homocysteinylation in Humans J. Nutr., February 1, 2000; 130(2): 377 - 377. [Abstract] [Full Text]

				H. JAKUBOWSKI Protein homocysteinylation: possible mechanism underlying pathological consequences of elevated homocysteine levels FASEB J, December 1, 1999; 13(15): 2277 - 2283. [Abstract] [Full Text]

				G. Liu, K. Nellaiappan, and H. M. Kagan Irreversible Inhibition of Lysyl Oxidase by Homocysteine Thiolactone and Its Selenium and Oxygen Analogues. IMPLICATIONS FOR HOMOCYSTINURIA J. Biol. Chem., December 19, 1997; 272(51): 32370 - 32377. [Abstract] [Full Text] [PDF]

				M. H. Moghadasian, B. M. McManus, and J. J. Frohlich Homocyst(e)ine and Coronary Artery Disease: Clinical Evidence and Genetic and Metabolic Background Arch Intern Med, November 10, 1997; 157(20): 2299 - 2308. [Abstract] [PDF]

				A. Majors, L. A. Ehrhart, and E. H. Pezacka Homocysteine as a Risk Factor for Vascular Disease : Enhanced Collagen Production and Accumulation by Smooth Muscle Cells Arterioscler Thromb Vasc Biol, October 1, 1997; 17(10): 2074 - 2081. [Abstract] [Full Text]

				H. Morita, J.-i. Taguchi, H. Kurihara, M. Kitaoka, H. Kaneda, Y. Kurihara, K. Maemura, T. Minamino, M. Ohno, K. Yamaoki, et al. Genetic Polymorphism of 5,10-Methylenetetrahydrofolate Reductase (MTHFR) as a Risk Factor for Coronary Artery Disease Circulation, April 15, 1997; 95(8): 2032 - 2036. [Abstract] [Full Text]

				H. Jakubowski and H. Jakubowski Metabolism of Homocysteine Thiolactone in Human Cell Cultures. POSSIBLE MECHANISM FOR PATHOLOGICAL CONSEQUENCES OF ELEVATED HOMOCYSTEINE LEVELS J. Biol. Chem., January 17, 1997; 272(3): 1935 - 1942. [Abstract] [Full Text] [PDF]